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Abstract The true burden of influenza in children is
difficult to assess and is probably underestimated as clinical
signs are usually nonspecific, and formal viral identification
is rarely searched. In this study, we compare the clinical
features of infections related to the new H1N1/09 influenza
virus with infections due to other respiratory viruses in
children consulting in a tertiary care pediatric hospital in
Geneva. Between October 1, 2009 and February 10, 2010,
109 patients were recruited, with a median of age of 7 years
(range 0.1–18). There were 75 H1N1/09-positive patients
(69%), and 32 (43%) had identified risk factors such as
asthma or a history of wheezing. Fever (87%), cough
(92%), and rhinitis (85%) were the most frequent reported
presenting symptoms in both patient groups. H1N1/09-
positive patients were significantly older (median of 8.2 vs.
4.6 years) and were more likely to have risk factors (43%
vs. 24%) and myalgias (41% vs. 20%). H1N1/09-negative
patients had more wheezing episodes (29% vs. 9%), higher
rates of dyspnea (28% vs. 20%) and of hospital admissions
(35% vs. 16%). Conclusion: Clinical signs cannot reliably
differentiate H1N1/09-positive and H1N1/09-negative
patients, although we found a higher proportion of myalgias
in H1N1/09-positive patients. Severity of disease was lower
in H1N1/09-positive than in H1N1/09-negative patients,
mostly because of a higher proportion of asthma/wheezing
episodes among H1N1/09-negative patients.
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Abbreviations
WHO World Health Organization
RSV Respiratory syncytial virus
ILI Influenza-like illness
RT-PCR Real-time polymerase chain reaction
NSAID Non-steroidal anti-inflammatory drugs
PICU Pediatric intensive care unit
PICO Picornavirus
ADV Adenovirus
PARA Parainfluenza virus
OB Obstructive bronchitis
Introduction
In spring 2009, an influenza A virus (H1N1/09) with a
unique combination of human, avian, and porcine genes
appeared in Mexico, and pandemia was declared on June
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11, 2009 by the World Health Organization (WHO) [25]. In
Switzerland, after a few imported cases during summer
2009, the epidemic threshold was reached during week 43,
peaked on week 49, and lasted until the end of March 2010.
Seasonal flu clinical signs are usually nonspecific, and
formal, laboratory-based, virological identification is rarely
demanded [18]. However, some difference in clinical
presentation can be recognized. For example, in a cohort
of 186 hospitalized children (126 respiratory syncytial virus
(RSV) and 60 influenza infections), Meury et al. found that
RSV-infected patients appear to have a higher rate of lower
respiratory tract infections than influenza A-infected
patients [16]. In this same study, febrile seizures were more
frequent among children admitted for influenza A and
influenza B infection compared to RSV-infected patients
[16]. For clinicians in emergency rooms and for general
practitioners, there is a need to use clinical features as a
basis for further use of specific diagnostic assays and to
define any medical intervention. The H1N1/09 pandemia
offered the ideal setting to evaluate the clinical presentation
of this new virus since children admitted to the emergency
room were systematically screened.
The aim of this study was to compare H1N1/09-positive
and H1N1/09-negative patients presenting to our emergency
department with an influenza-like illness (ILI) during the
2009 pandemia. Our secondary objective was to study the
determinants for hospitalization among H1N1/09-positive
patients and to compare H1N1/09-positive and H1N1/09-
negative children presenting with wheezing or seizures.
Population and methods
Design and setting
This study is a prospective case–control study in a tertiary
care pediatric hospital in Geneva (Hôpital des Enfants,
University Hospitals of Geneva) during the epidemic wave
of 2009–2010 H1N1/09 influenza pandemia. Children of
equal or less than 18 years old consulting in the emergency
department, during daytime (8:00 A.M.–8:00 P.M.) of week-
days, presenting with ILI (fever ≥38° with signs of upper
and/or lower respiratory tract infection, according to the
WHO definition [24]), or a febrile seizure after H1N1/09
reached the epidemic threshold in the area were approached
for participation in the study. Legal guardians—and the
children, when appropriate—signed a written informed
consent. Past medical history and current reason for the
visit were recorded on a common case report form using the
information in the medical charts and by interviewing the
parents (and the child).
This study was approved by the institutional ethics
committee, and conducted in accordance with the principles
of the Declaration of Helsinki, the standards of Good
Clinical Practice, and Swiss regulatory requirements.
H1N1/09 diagnosis and treatment
Enrolled children had a nasopharyngeal swab to perform an
influenza real-time polymerase chain reaction (RT-PCR) to
confirm either pandemic, seasonal (non-pandemic) influenza
A, or influenza B infection. RT-PCR result was obtained
within two working days. In addition, wheezing patients also
had a PCR to detect the presence of other viral infections, such
as RSV, picornavirus, adenovirus, or parainfluenza virus. RT-
PCR assays for influenza and other respiratory viruses'
detection were performed according to standardized proto-
cols running in our virology laboratory [10, 20], which is
also a WHO referral center for influenza. The primers and
probes used for the H1N1/09 detection targeted the N1 gene
and were specifically adapted to the circulating strains
(forward primer 5′-AGACCTTGCTTCTGGGTTGA-3′, re-
verse 5′-ACCGTCTGGCCAAGACCA-3′, probe 5′-FAM-
ATCTGGACTAGCGGGAGCAGCAT-TAMRA). This assay
was used in parallel of another PCR targeting the M genes of
human seasonal influenza A viruses [10, 20].
According to national recommendations published in
August 2009 [19], oseltamivir was used to treat possibly
infected patients at risk of complications (including infants
below 12 months of age), those with severe manifestations,
or in close contact with at-risk patients [22]. Patients were
considered at risk if they had a cardiopathy, a chronic
pneumopathy (such as asthma, recurrent obstructive bronchitis/
bronchiolitis, cystic fibrosis, or bronchodysplasia), a neuro-
muscular disease affecting the pulmonary function, an immu-
nodeficiency (congenital or acquired, including sickle-cell
disease), a metabolic disease (affecting the heart, the lungs,
the kidney, or the immune system), or prematurity (less than
33 weeks of gestation or 1,500 g at birth in children less than
2 years of age). Children were treated with oseltamivir twice a
day for 5 days if H1N1/09 was positive by PCR or stopped in
case of a negative PCR result.
Statistical analysis
Statistical analyses were performed with SPSS (SPSS
version 15.0; SPSS Inc., Chicago, IL, USA). Demographics,
other basic characteristics, and outcome measures between the
groups were compared with chi-square test for categorical
variables and with Mann–WhitneyU test or Student's t test for
continuous variables, as appropriate. Two-sided p value <0.05
was considered statistically significant.
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Results
Description of the population
Between October 1, 2009 and February 10, 2010, 109
patients were included in the study (Fig. 1). Their median
age was 7 years (range 0.1–18 years). The majority of
patients (95%) presented with signs of respiratory tract
infection, and less than 20% had a wheezing episode. Only
five patients (5%) presented with a febrile seizure. Seventy-
five children (69%) tested positive for H1N1/09 infection.
There was no positive result for seasonal influenza.
Characteristics of the population
H1N1/09-positive patients were significantly older (median
age of 8.2 years old, range 0.1–18) than H1N1/09-negative
patients (4.6 years old, range 0.1–15; p=0.002; Table 1).
There was no difference in gender and ethnicity between
the H1N1/09-positive and H1N1/09-negative groups.
H1N1/09-positive children had a greater proportion of
high-risk medical condition (43% vs. 24%, p=0.04) than
H1N1/09-negative children and were more likely to have
received seasonal flu immunization the same year (20% vs.
3%, p=0.02). Overall, 7% of our population received
H1N1/09 vaccine, without any difference between H1N1/
09-positive and H1N1/09-negative patients. The main risk
factor in both groups was a past history of asthma or
wheezing (62% of all risk factors in H1N1/09-positive and
44% in H1N1/09-negative patients). In the H1N1/09-
positive group, immunosuppression was the second most
frequent medical condition (31%) followed by hemoglo-
binopathy (10%), neuropathy (9%), chronic pneumopathy
(3%), and prematurity (3%). In the H1N1/09-negative group,
the second most frequent medical condition was neuropathy
(25%), followed by cardiopathy (13%). There was no
significant difference in the overall distribution of risk factors
among groups. Median delay for consultation after onset of
symptomswas not significantly different between groups with
an overall median of 1 day (range 0–9).
Clinical presentation
When we compared the three clinical presentations (respiratory
tract infections without wheezing, wheezing, and seizure), we
found that wheezing episodes were more frequent in H1N1/09-
negative patients (Table 2).
Cough (92%), fever (87%), and rhinitis (85%) were the
most commonly reported symptoms in both groups without
significant difference between H1N1/09-positive (93%,
91%, 87%, respectively), and H1N1/09-negative patients
(88%, 79%, and 82%, respectively) (Fig. 2). The 13% of
patients who did not report fever as symptom had
temperature equal to or more than 38 C measured in the
emergency room. Myalgias were more frequent in H1N1/
09-positive patients (41% vs. 20%, p=0.04), and dyspnea
were more frequent in H1N1/09-negative patients (28% vs.
20%, p=0.05). H1N1/09-positive patients used more non-
steroidal anti-inflammatory drugs (NSAIDs) than H1N1/09-
negative patients (48% vs. 27%, p=0.04). At enrollment,
there were 18 patients (17%), which already had received
oseltamivir with no significant difference between H1N1/
09-positive (13/75, 17%) and H1N1/09-negative (5/29,
15%) patients.
Management
Fifty-one (68%) H1N1/09-positive patients were prescribed
with oseltamivir before influenza PCR results were available,
compared to 8 (24%) H1N1/09-negative patients (p<0.001).
Of these patients, 12/51 H1N1/09-positive and 3/8 negative
children began their treatment before enrollment. Subse-
quently, treatment was stopped in three H1N1/09-positive
patients. Among clinical and basic characteristics (age,
ethnic group, clinical presentation, risk factor), risk factor
appears to be the only significant determinant of oseltamivir
prescription before reception of H1N1/09 PCR result in
the entire population and in H1N1/09-positive patients
(p<0.001). Two at-risk patients (one asthmatic child and
one patient with an immunosuppressive treatment for
Crohn's disease) out of 32 H1N1/09-positive patients
(6%) did not receive oseltamivir. The hospitalization rate
was higher among H1N1/09-negative patients (12 (35%)
vs. 12 (16%), p=0.04). Suspected bacterial complications
were present in 12% of patients (nine cases of pneumonia,
three cases of acute otitis media, and one case of sinusitis)
and were similar in both groups. Seventeen patients (16%)
received antibiotics, without any differences between
H1N1/09-negative and H1N1/09-positive patients.Fig. 1 Description of the population
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Hospitalization among H1N1/09-positive patients
Twelve H1N1/09-positive patients (16%) were hospitalized.
Nine hospitalized patients had risk factors (75%) compared
to 23 outpatients (37%) (p=0.02). There were more
wheezing episodes among hospitalized patients (25% vs.
6%, p = NS). Four hospitalized patients were prescribed
oseltamivir before enrollment compared to nine not
hospitalized patients (14%) (p = NS). The main reason
for hospitalization was a respiratory tract infection (8/12).
One patient was admitted for surveillance because of
underlying sickle-cell disease. Three patients had a
nosocomial H1N1/09 influenza infection: one was hospi-
talized for a neurosurgical intervention, the second for an
exacerbation of Crohn's disease and the third was a
premature neonate. The source of their infection was not
identified. Half of the hospitalized H1N1/09-positive
patients developed a bacterial infection (five pneumonias
(four radiologically confirmed) and one clinical sinusitis).
All hospitalized patients received oseltamivir (either
prescribed at or before admission) and 6/12 needed
oxygen therapy for a median duration of 2.5 days (range
1–12 days). Four patients were admitted in the pediatric
intensive care unit (PICU): two for a severe pneumonia,
one for a respiratory surveillance of a pneumonia because
of a risk factor (sickle-cell disease), and one was already
in the PICU for a post-neurosurgery management. No
patient needed mechanical ventilation. Median duration of
hospitalization for non-nosocomial cases was 3 days
(range 2–37 days).
Table 2 Clinical presentation and treatment of 109 children with influenza-like illness with or without positive H1N1/09 infection confirmed by PCR
Characteristic Total n=109 H1N1/09+ n=75 H1N1/09 n=34 P value
Duration of symptoms
Median (range)—days 1 (0–9) 1 (0–7) 2 (0–9) NS
Clinical category 0.02
Wheezing 17 (15%) 7 (9%) 10 (29%)
Respiratory (non-wheezing) 87 (80%) 64 (86%) 23 (68%)
Seizure 5 (5%) 4 (5%) 1 (3%)
Treatment received before enrollment
Antibiotics 11 (10%) 7 (9%) 4 (12%) NS
Oseltamivir 18 (17%) 13 (17%) 5 (15%) NS
Paracetamol 83 (76%) 59 (79%) 24 (71%) NS
Non steroidal anti-inflammatory drugs 45 (41%) 36 (48%) 9 (27%) 0.04
Vital signs at enrollment
Temperature—mean (range) 37.65 (36.3–40.4) 37.7 (36.3–40.4) 37.45 (36.3–39.9) NS
Respiratory rate mean/min (range) 28 (10–56) 26 (12–54) 31.5 (10–56) 0.06
Heart rate pulse/min (range) 120 (52–190) 117 (52–190) 124 (80–181) NS
Table 1 Characteristics of 109 children with influenza-like illness at the emergency department during the H1N1/09 pandemia
Characteristic Total n=109 H1N1/09 PCR positive n=75 H1N1/09 PCR negative n=34 P value
Age at consultation, median, in years (range) 7 (0.1–18) 8.2 (0.1–18) 4.6 (0.1–15) 0.002
Gender, male, n (%) 64 (58%) 40 (53%) 24 (71%) NS
Caucasian ethnicity 66 (62%) 43a (59%) 23 (67%) NS
Risk factor, n (%) 40 (37%) 32 (43%) 8 (24%) 0.04
Vaccination
General vaccinations up-to-date 99 (93%) 68 (93%) 31 (94%) NS
Seasonal flu 2009 vaccine 16 (15%) 15 (20%) 1 (3%) 0.02
H1N1/09 vaccine 8 (7%) 7 (10%) 1 (3%) NS
Risk factors (% H1N1/09+/H1N1/09−), asthma/wheezing (44/62), immunosuppression (31/0), sickle-cell disease (10/0), neurologic disease (9/25),
chronic pneumopathy (3/0), cardiopathy (0/13), prematurity (3/0)
a Two patients: unknown ethnicity
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Wheezing
Seventeen patients presented with wheezing episodes (Table 3).
Seven patients (41%) were H1N1/09 positive and ten (59%)
H1N1/09 negative. Median age was 5.8 years (range 0.1–15).
H1N1/09-positive patients were older (median age 5.8, range
1.4–15) than H1N1/09-negative patients (median age 4, range
0.1–10.3) (p=0.06). All H1N1/09-positive wheezing patients
had a risk factor (all with a past history of recurrent wheezing
episodes), unlike the H1N1/09-negative patients (4/10; p=
0.03). Among these, three patients also had a history of
recurrent wheezing episodes, and one had a chronic neuro-
logical disease. There was no difference in the presenting
symptoms, vital signs or management, except for oseltamivir
prescription (100% for H1N1/09-positive patients compared
to 20% for H1N1/09-negative patient, p=0.002). Only one
H1N1/09-positive patient and no H1N1/09-negative patient
developed pneumonia. Eleven (65%) wheezing patients were
hospitalized: 8 H1N1/09-negative patients (80%) compared to
3 H1N1/09-positive patients (43%; p = NS). One H1N1/09-
positive patient had a viral co-infection (H1N1/09+picornavi-
rus+adenovirus). Among H1N1/09-negative patients, picor-
navirus was the most prevalent viral etiology (60%) followed
by RSV (40%), adenovirus (20%), and parainfluenza virus
(10%). Three patients had co-infections (RSV + adenovirus,
RSV + picornavirus, and adenovirus + parainfluenza).
Febrile seizures
Five patients presented with a febrile seizure at a median
age of 3.5 years (range 2–13.6). Four out of five were
H1N1/09 positive. Two children (one H1N1/09 positive and
Fig. 2 Comparison of clinical
findings in 109 children with
influenza-like illness with or
without positive H1N1/09
infection confirmed by PCR.
Asterisks indicate significant
difference (p≤0.05)
Table 3 Characteristics of children presenting with wheezing during the study period
Age (years) Preexisting condition Clinical presentation Length of hospital stay (days) PCR result
0.1 None Bronchiolitis 6 RSV
0.4 None Bronchiolitis 8 RSV+ADV
0.4 None Bronchiolitis 3 RSV
1.4 Wheezing OB 3 H1N1/09+PICO+ADV
1.5 None OB 3 ADV+PARA
2.6 None OB 2 PICO
5.2 Wheezing OB 0 H1N1/09
5.3 Wheezing Asthma 0 PICO
5.8 Wheezing OB 0 H1N1/09
5.8 Wheezing OB 3 H1N1/09
5.9 Wheezing Bronchitis 0 PICO
7.7 Wheezing Asthma 4 PICO
7.8 Cerebral palsy OB 4 RSV+PICO
10.3 None Asthma 0 PICO
13.5 Wheezing Asthma 6 H1N1/09
13.7 Wheezing Asthma 0 H1N1/09
15 Wheezing Asthma 0 H1N1/09
RSV respiratory syncytial virus, PICO picornavirus, ADV adenovirus, PARA parainfluenza virus, OB obstructive bronchitis
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one H1N1/09 negative) had a chronic neurological disease.
One H1N1/09-positive patient was hospitalized.
Discussion
Our study confirms that clinical presentation cannot reliably
differentiate ILI of influenza etiology from other viral
causes, as it was already described for seasonal influenza
[18]. However, H1N1/09-positive patients appear older, are
more likely to have a risk factor, and complain more
frequently of myalgias, which can explain a greater use of
NSAID. The clinical course of new H1N1/09 influenza
virus in children was more benign in our community than
expected for a new pandemic virus. Moreover, in our
epidemiological context, respiratory tract infections from
causes other than H1N1/09 appeared more severe, as shown
by a greater proportion of dyspnea, and a higher hospital-
ization rate in H1N1/09-negative children, associated with a
greater proportion of wheezing episodes.
H1N1/09 was recently associated with severe clinical
syndromes in children, such as hypoxemic syndrome
requiring mechanical ventilation [9], organ failure pattern
[14], or even neurologic complications [2, 21]. However, in
other reports, when compared to seasonal influenza,
pandemic H1N1/09 influenza did not appear to have a
more severe course [1, 3, 17]. Differences in studied
populations and in screening and treatment strategies could
explain differences in reported severity. Jouvet et al.
described that severe illness was common among aboriginal
children [9]. Farias et al. found a positive effect of
oseltamivir on survival when it was administered within
24 h of admission to PICU [7], and Hiba et al. demonstrate
that early (<48 h) administration of oseltamivir could
protect hospitalized adults from H1N1/09 complications
[8]. Our patients consulted rapidly after the first symptoms
(median of 1 day) and could receive oseltamivir promptly,
which could have a protective effect. Moreover, H1N1/09-
positive patients received oseltamivir more frequently
before PCR result than H1N1/09-negative patients. The
higher proportion of risk factors in this population dictated
the prescription of antiviral treatment. Thus, only 2/32 at-
risk H1N1/09-positive patients did not receive oseltamivir.
Risk factors have a predominant role in the severity of
the disease. In our study, the prevalence of risk factors was
significantly higher in H1N1/09-positive patients than in
H1N1/09-negative patients and two thirds of our hospital-
ized H1N1/09-positive patients had a risk factor compared
to only one third among outpatients. Similarly, in case
series of hospitalized patients, risk factors—lung diseases
being the most prevalent—were highly prevalent [12] and
associated with a greater risk of severe disease [5],
including that of being admitted to PICU [9]. In an
outpatient setting, Mahut et al. showed that ILI and severe
exacerbation are significantly and strongly associated in the
H1N1 influenza pandemic in asthmatic children [15].
Finally, in the USA, Cox et al. found that the majority of
pediatric deaths from H1N1/09 were in older children with
high-risk medical conditions [6]. As a prevention strategy,
vaccination could have offered an important protection to our
vulnerable population. Unfortunately, H1N1/09 vaccines were
only available at or after the epidemic peak. It explains why
only 7% of our population received this vaccine.
Libster et al., in a hospitalized series in Argentina, report
wheezing in 16% (39/251) of their patients [13]. This is
higher than the percentage of wheezing in our H1N1/09
population but lower than the proportion in our hospitalized
population. This confirms that wheezing increases the risk
of hospitalization. Interestingly, these authors also describe
a subset of 47 patients who had H1N1/09 influenza with a
viral coinfection. In this subpopulation, when compared
with H1N1/09 infection alone, proportions of wheezing,
oxygen supply, admission to PICU, and use of mechanical
ventilation were higher. These findings are in concordance
with the results of our study. However, in another study,
Tresoldi et al. reported a higher proportion (66%) of
wheezing among hospitalized H1N1/09-positive patients
when compared to H1N1/09-negative patients (52%, p = NS)
[23]. In this same study, clinical course appeared more severe
for H1N1/09-positive patients according to a higher propor-
tion of PICU admission (47% vs. 11%, p=0.002) and three
deaths among the 15 H1N1/09-positive patients. So, con-
clusions of this study appear to be different from ours.
Nevertheless, comparisons seem to be difficult according to
difference in study population and setting (Brazil, only
hospitalized patients), in screening strategies (no research of
viral co-infection in wheezing patients), and longer delay for
consultation (median of 4 days).
The source of nosocomial infections could not be traced,
but as H1N1/09 vaccination rates were 50% among health-
care workers in our center, and 14% in the general national
population at the end of the pandemic, it is likely that the
virus was transmitted via the hospital staff or visitors.
Our study has a major limitation. In our recruitment
strategy, we did not include patients, who consulted during
evening, night, and weekend hours, but enrolled them next
day if they were admitted. Consequently, the calculated
hospitalization rate may be overestimated. For comparison,
in two outpatient studies, hospitalization rate of H1N1/09-
positive patients was 4% and 11% [4, 11]. However, we
believe that this bias affected similarly H1N1/09-positive
and H1N1/09-negative children and did not have a major
impact on our results. Another limitation was the selection
of at-risk patients. They were advised to consult immedi-
ately in case of ILI to receive oseltamivir treatment. Most of
the other patients did not consult at all or were seen in
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private practice. Nevertheless, our institution is the only
center in our area to hospitalize pediatric patients. One
more limitation was that only wheezing patients had in
addition PCR for other respiratory viruses. Some H1N1/09-
positive patients could have had viral co-infections.
However, as only one H1N1/09 positive wheezing patient
had a co-infection, we hypothesize that prevalence of co-
infection in H1N1/09 was not significantly high. Higher
prevalence of co-infection in H1N1/09-negative patients
may also have increased severity in this population. This
cannot be excluded.
This is the first prospective study comparing the clinical
features of H1N1/09 influenza with those of other seasonal
respiratory viruses that include a comparison of risk factors
and wheezing episodes. Thus, we were able to demonstrate
that risk factors have a greater role in H1N1/09-positive
population, which should motivate us to achieve a much
better immunization rate, and that wheezing is more
prevalent in H1N1/09-negative patients, which is related
to a relative greater severity of disease in our setting.
Oseltamivir was rapidly given to our at-risk patients and
could have contributed to the relative benignity of H1N1/09
infections in our setting. Finally, we confirm that clinical
signs do not reliably differentiate ILI caused by H1N1/09
from other viral etiology in children.
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